O
AGMB

OrbiMed’s AgomAb Therapeutics NV AGMB Stock Holding History

OrbiMed’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.5M Buy
+192,740
New +$2.17M 0.05% 116

Other funds holding AGMB

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed's AGMB Position: Q2 2026 in Review

OrbiMed opened a new position in AgomAb Therapeutics NV (AGMB) in Q2 2026: 192,740 shares worth $2.5M. The stake represents 0.05% of the portfolio and ranks #116 among its holdings.

34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

  • OrbiMed held 192,740 shares of AgomAb Therapeutics NV worth $2.5M as of Q2 2026.
  • AgomAb Therapeutics NV was a new OrbiMed position in Q2 2026.
  • AgomAb Therapeutics NV made up 0.05% of OrbiMed's portfolio in Q2 2026, its #116 holding.
  • 34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.